Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review

Código QR

Efficacy of Glucagon-Like Peptide-1 Analogs in Nonalcoholic Fatty Liver Disease: A Systematic Review

Getnet Teshome,1 Sintayehu Ambachew,2 Alebachew Fasil,2 Molla Abebe2 1University of Gondar Comprehensive Specialized Hospital, University of Gondar, Gondar, Amhara, Ethiopia; 2Department of Clinical Chemistry, University of Gondar, Gondar, Amhara, EthiopiaCorrespondence: Getnet TeshomeUniversity of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Teshome G, Ambachew S, Fasil A, Abebe M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	glp-1ra glp-1 analogues glp-1 and nafld Diseases of the digestive system. Gastroenterology RC799-869
Acceso en línea:	https://doaj.org/article/9ee83a335def4fcb878696f4dcd4d95e
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Activation of ectopic olfactory receptor 544 induces GLP-1 secretion and regulates gut inflammation
por: Chunyan Wu, et al.
Publicado: (2021)

Clinical Impact of Liraglutide as a Treatment of Obesity
por: Alruwaili H, et al.
Publicado: (2021)

The role of human glucagon-like peptide-1 analog in therapy of type 2 dianetes mellitus
por: Marina Vladimirovna Shestakova
Publicado: (2010)

Glucagon-Like Peptide 1 Attenuates Lipotoxicity-Induced Islet Dysfunction in ApoE–/– Mice
por: Liu F, et al.
Publicado: (2020)

Degradation of the Incretin Hormone Glucagon-Like Peptide-1 (GLP-1) by <named-content content-type="genus-species">Enterococcus faecalis</named-content> Metalloprotease GelE
por: Stephanie L. LeValley, et al.
Publicado: (2020)

A Review of Current Trends with Type 2 Diabetes Epidemiology, Aetiology, Pathogenesis, Treatments and Future Perspectives
por: Reed J, et al.
Publicado: (2021)

Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
por: Chudleigh RA, et al.
Publicado: (2020)

Analysis Of Risk Factors For Nonalcoholic Fatty-Liver Disease In Hepatitis B Virus Infection: A Case–Control Study
por: Azarkar G, et al.
Publicado: (2019)

Surgical treatment of nonalcoholic fatty liver disease in severely obese patients
por: Vander Naalt SJ, et al.
Publicado: (2014)

Tyrosine levels are associated with insulin resistance in patients with nonalcoholic fatty liver disease
por: Kawanaka M, et al.
Publicado: (2015)

Association between liver fibrosis progression and endothelin-1/nitric oxide in patients with nonalcoholic fatty liver disease
por: LI Pinhua
Publicado: (2021)

Glucagon-like peptide-1 exerts anti-inflammatory effects on mouse colon smooth muscle cells through the cyclic adenosine monophosphate/nuclear factor-κB pathway in vitro
por: Al-Dwairi A, et al.
Publicado: (2018)

A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis
por: Ganguli S, et al.
Publicado: (2019)

Simultaneous Effect of Resveratrol and Probiotics on Insulin Resistance and Glucagon-Like Peptide (GLP-1) Levels in Diabetic Rats
por: A Pegah, et al.
Publicado: (2021)

GLP-1 Receptor Agonist Effects on Lipid and Liver Profiles in Patients with Nonalcoholic Fatty Liver Disease: Systematic Review and Meta-Analysis
por: Shahla Rezaei, et al.
Publicado: (2021)

A lipid-rich gestational diet predisposes offspring to nonalcoholic fatty liver disease: a potential sequence of events
por: Hughes AN, et al.
Publicado: (2014)

Hepatocyte-specific TM6SF2 knockout aggravates hepatic steatosis in mice with nonalcoholic fatty liver disease
por: ZHANG Jie
Publicado: (2021)

First GLP-1 analog liraglutide: the result of clinical trails on efficacy
por: Alexander Sergeevich Ametov, et al.
Publicado: (2011)

White Adipose Tissue Autophagy and Adipose-Liver Crosstalk Exacerbate Nonalcoholic Fatty Liver Disease in MiceSummary
por: Sadatsugu Sakane, et al.
Publicado: (2021)

A serum metabolomics study on the intervention of nonalcoholic fatty liver disease by equicaloric low-carbohydrate high-protein diet combined with aerobic exercise
por: LI Meiying
Publicado: (2021)

Modern antihyperglycemic agents prescribed in Russia for type 2 diabetes mellitus
por: Yury Ivanovich Suntsov
Publicado: (2012)

Emerging role of GLP-1 receptor agonists in the treatment of obesity
por: Neff LM
Publicado: (2010)

Diseño y Evaluación de Mezcladores de un Quemador Doméstico usando Gas Licuado de Petróleo
por: Rojas,Freddy J, et al.
Publicado: (2017)

Riesgos Hacia los Trabajadores y Comunidad por Liberaciones Accidentales de Gases Densos Peligrosos en la Ciudad de Los Ángeles (Chile)
por: Silva,Adrián, et al.
Publicado: (2016)

Modelación de Riesgos Hacia los Trabajadores y Comunidad por Emisiones de Gas Licuado de Petróleo, Utilizando Software Slab View en la Ciudad de Los Ángeles, Chile
por: Silva,Adrián, et al.
Publicado: (2017)

Different antihyperglycaemic drug effects on glycaemic variability in Type 2 diabetic patients
por: Alina Babenko, et al.
Publicado: (2014)

Lifestyle interventions for the treatment of non-alcoholic fatty liver disease
por: Bradford V, et al.
Publicado: (2013)

Activation of the GLP-1 receptor by chloropyrimidine derivatives
por: Shaikha S. AlNeyadi, et al.
Publicado: (2021)

Prevalence rate of non-obese fatty liver disease and related influencing factors
por: DENG Jiang
Publicado: (2021)

Treatment of nonalcoholic steatohepatitis with vitamins E and C: a pilot study
por: Kawanaka M, et al.
Publicado: (2013)

Endoscopic duodenal mucosal resurfacing for nonalcoholic steatohepatitis (NASH): a pilot study
por: Alia Hadefi, et al.
Publicado: (2021)

FIB-4, APRI, and AST/ALT ratio compared to FibroScan for the assessment of hepatic fibrosis in patients with non-alcoholic fatty liver disease in Bandar Abbas, Iran
por: Behnaz Amernia, et al.
Publicado: (2021)

Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt
por: Osama Hamdy, et al.
Publicado: (2021)

Advances in the treatment of type 2 diabetes: impact of dulaglutide
por: Thompson AM, et al.
Publicado: (2016)

Autophagy: a new target for nonalcoholic fatty liver disease therapy
por: Mao YQ, et al.
Publicado: (2016)

Universal Index for Cirrhosis (UIC index): The development and validation of a novel index to predict advanced liver disease
por: Ahmed Z, et al.
Publicado: (2018)

The dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist tirzepatide: a novel cardiometabolic therapeutic prospect
por: Enrique Z. Fisman, et al.
Publicado: (2021)

PI3Kγ promotes obesity-associated hepatocellular carcinoma by regulating metabolism and inflammation
por: Barbara Becattini, et al.
Publicado: (2021)

GLP-1 mediates the modulating effect of thymoquinone on feeding behaviors in diabetic rats
por: Lee SP, et al.
Publicado: (2019)

Adherence to GLP-1 receptor agonist therapy administered by once-daily or once-weekly injection in patients with type 2 diabetes in Germany
por: Qiao Q, et al.
Publicado: (2016)